1369414-22-1

Upstream product

• 1420775-79-6 4-amino-3-(4-(3-(3-fluorophenyl)ureido)phenyl)thieno[3,2-c]pyridine-7-carboxylic acid 
• 104-78-9 diethylaminopropylamine 
• 1420775-77-4 1-(4-(4-amino-7-iodothieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea 

Relevant academic research and scientific papers

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

KINASE INHIBITOR WITH IMPROVED AQUEOUS SOLUBILITY

4-Amino-N- [3 -(diethylamino)propyl]-3 -(4- { [(3 - fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2-c]pyridine-7-carboxamide which inhibits protein kinases such as Aurora-kinases and the VEGFR and PDGFR families of kinases, with an improved aqueous solubility profile, compositions containing 4-amino-N-[3- (diethylamino)propyl]-3-(4- {[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2- c]pyridine-7-carboxamide and methods of treating diseases using 4-amino-N-[3- (diethylamino)propyl]-3-(4- {[(3-fluorophenyl)carbamoyl]amino}phenyl)thieno[3,2- c]pyridine-7-carboxamide are disclosed.